A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)
Phase 2
620
about 2.5 years
18–79
28 sites in CA, FL, IL +5
About this study
This trial is testing a treatment called PF-07328948 for people with heart failure. Participants will take either PF-07328948 or a placebo, once daily, for 36 weeks to see if it's safe and effective compared to a placebo in people already taking standard medications for heart failure.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take High Dose PF-07328948
- 2.Take Low Dose PF-07328948
- 3.Take Medium Dose PF-07328948
- +1 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Change From Baseline in 6-Minute Walk Test (6MWD), Change From Baseline in Kansas City Cardiomyopathy Questionnaire Overall Total Symptom Score (KCCQ-23 TSS)
Secondary: CPET Substudy) : Change From Baseline in Peak Oxygen Consumption (pVO2) at Week 36, Change From Baseline in 6-minute walk test distance (6MWD) in participants taking PF-07328948 vs. placebo on HF disease-specific health status related to HFmrEF/HFpEF., Change From Baseline in Kansas City Cardiomyopathy Questionnaire Overall Symptom Score (KCCQ-23 TSS) and physical limitation in participants taking PF-07328948 vs. placebo on HF disease-specific health status related to HFmrEF/HFpEF., Change From Baseline in Kansas City Cardiomyopathy Questionnaire Overall clinical symptom Score (KCCQ-23 CSS) and physical limitation) in participants taking PF-07328948 vs. placebo on HF disease-specific health status related to HFmrEF/HFpEF., Change From Baseline in N-Terminal Prohormone Brain Natriuretic Peptide (NT-proBNP) Concentration at Week 36, Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
Cardiology / Heart